Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8162618 | 0.81 | CA12 (0.45) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL7149802 | 0.80 | CA12 (0.32) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL2548868 | 0.79 | CA12 (0.44) | CA12CA1CA9PREP | |
| SCHEMBL7139756 | 0.78 | ABL1 (0.31) | CA12CA1CA9 | |
| SCHEMBL24677984 | 0.76 | ALDH1A1 (0.39) | CA12CA1CA9 | |
| SCHEMBL2597426 | 0.74 | CA12 (0.42) | CA12CA1CA9PREP | |
| SCHEMBL8466480 | 0.74 | MEN1 (0.40) | CA12CA1CA9 | |
| SCHEMBL5037971 | 0.74 | TRPA1 (0.40) | — | |
| SCHEMBL4977539 | 0.72 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL23190575 | 0.72 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548694-B2 | Anticoagulants | HOFFMAN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1289939-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | US | disclosed |
| WO-2001090051-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | GLS, SLC6A5, GLRA1 | CA12 1082/4885CA1 251/4885CA9 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.